A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in duodenal ulcer healing.

Abstract

A randomised multicentre, double-blind study of the efficacy and safety of roxatidine acetate 150 mg at bedtime or 75 mg twice a day was conducted in 300 outpatients with endoscopically confirmed duodenal ulcers. After 14 days' treatment with roxatidine acetate substantial reductions in ulcer sizes had been obtained, in addition to healing rates of 87 to 89%, with no significant differences between the dosage regimens. There were graded reductions in day and night-time assessment of epigastric pain for both treatment groups and no differences in the mean numbers of antacid tablets consumed. In addition, cigarette smoking did not influence the healing rates produced by either treatment schedule. 11 patients reported 12 mild adverse reactions, with gastrointestinal symptoms the most frequent, and no clinically significant alterations in laboratory values. The present data suggests that a single bedtime dose of roxatidine acetate 150 mg produces effective duodenal ulcer healing and pain relief equivalent to that produced by a twice daily dosage regimen.

• Authors: E Hentschel, K Schütze
• Journal: Drugs (Drugs) Vol. 35 Suppl 3 Pg. 96-101 ( 1988) ISSN: 0012-6667 [Print] New Zealand
• PMID: 2905256 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Histamine H2 Antagonists
• Piperidines
• TZU 0460

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (complications, drug therapy)
• Female
• Histamine H2 Antagonists (administration & dosage, adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Piperidines (administration & dosage, adverse effects, therapeutic use)
• Random Allocation
• Smoking (adverse effects)